Fiasp Vials 10 ml 100 Units / mL. Fiasp 100IU/ml Solution for injection is used for blood sugar control in individuals who have been diagnosed with type 1 and type 2 diabetes. It helps lower blood sugar levels after meals. Further, it reduces the chance of developing any diabetes complications, including kidney damage, nerve problems, loss of limbs, or eye damage.
Your doctor may prescribe Fiasp 100IU/ml Solution be used with a long-acting type of insulin or other medications for diabetes.
Fiasp (insulin aspart) vials are fast-acting insulin that closely matches the natural physiological insulin produced after a meal by a person who does not have diabetes. To increase the speed of absorption, Fiasp has included Vitamin B3 (niacinamide) as it is also used for stability, L-Argenine, a natural amino acid.
Unlike other common brands of insulin, Fiasp has a more flexible dosing regimen that allows you to inject up to 2 minutes before starting a meal or up to 20 minutes after starting a meal without compromising your overall safety and glycemic control. Fiasp Vials 10 ml 100 Units / mL
Ensure you are ordering the correct insulin, as insulin aspart is available by Novolin in pens, vials and cartridges.
Fiasp insulin is also available through FlexTouch pens and cartridges
1 mL of the solution contains 100 units of insulin aspart* (equivalent to 3.5 mg).
Fiasp 100 units/mL solution for injection in vial
Each vial contains 1,000 units of insulin aspart in 10 mL solution.
*Insulin aspart is produced in Saccharomyces cerevisiae by recombinant DNA technology.
For the full list of excipients, see section 6.1.
Solution for injection.
Clear, colourless, aqueous solution.
Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
Posology
Fiasp is a mealtime insulin for subcutaneous administration up to 2 minutes before the start of the meal, with the option to administer up to 20 minutes after starting the meal (see section 5.1).
Dosing with Fiasp is individual and determined in accordance with the needs of the patient. Fiasp given by subcutaneous injection should be used in combination with intermediate-acting or long-acting insulin given at least once a day. In a basal-bolus treatment regimen approximately 50% of this requirement may be provided by Fiasp and the remaining by intermediate-acting or long-acting insulin.
The individual total daily insulin requirement in adults, adolescents and children may vary and is usually between 0.5 and 1 unit/kg/day.
Blood glucose monitoring and insulin dose adjustment are recommended to achieve optimal glycaemic control.